ArticleIndian heart journal
Left ventricular ejection fraction and outcomes following PCI in STEMI and other acute coronary syndromes: ACC NCDR registry in India.
Article in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess influence of echocardiographic left ventricular ejection fraction(LVEF) on outcomes following percutaneous coronary intervention(PCI) in ST-elevation myocardial infarction(STEMI) and other acute coronary syndromes(oACS).
methodsSuccessive patients with ACS who underwent PCI from April'2019 to March'2022 were enrolled, while those who did not undergo PCI were excluded. In all patients, LVEF was obtained at hospital admission and classified into <30.0%,30.0-39.9%,40.0-49.9% and ≥50.0%. Details of risk factors, coronary angiography, interventions, management, and in-hospital and 3-year outcomes were obtained. Multivariate Cox-proportionate hazard ratios(HR) and 95% confidence intervals(CI), adjusted for age, sex, risk factors, presentation, angiography, interventions, management, and hospitalisation, for major adverse cardiovascular events(MACE) and deaths were calculated.
resultsData of 3789 patients (men 3011, women 778) with ACS (STEMI = 1601; oACS = 2188) were available at baseline and 3.0yr (IQR 2.1-4.0) median follow-up. STEMI patients were younger, with more men, smoking, hypercholesterolemia, impaired LVEF, vasopressor support, hospitalisation duration, and in-hospital deaths vs oACS (p < 0.01). Important determinants of reduced LVEF were smoking, 3-vessel, left-main or left anterior descending CAD (p < 0.01). In both groups, patients with lower LVEF(<30.0%,30.0-39.9%) had more in-hospital deaths (p < 0.05). At 3-year follow-up, compared to LVEF >50.0%, multivariate-adjusted HR(95%CI) in LVEF<30.0% for MACE [STEMI 8.55(3.04-24.03); oACS 2.71(1.39-5.29)] as well as CV deaths [STEMI 16.50(3.64-74.71); oACS 3.72(1.40-9.85)] were significant (p < 0.001). For LVEF 30.0-39.9% group, HRs were of borderline significance [STEMI 2.26(0.86-5.89);oACS 1.34(0.76-2.36)] and not significant for LVEF 40.0-49.9% group. Outcomes were not significantly different in men and women.
conclusionsSTEMI and other ACS patients undergoing PCI with LVEF<30% have significantly higher in-hospital and 3-year major adverse cardiovascular events and deaths.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.